Reactive and proactive treatment in atopic dermatitis: Long-term disease control
Indian Journal of Skin Allergy · 27.10.2023 · 2 · 45-50
DOI: 10.25259/ijsa_31_2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Skin Allergy, online erschienen am 27.10.2023. Verfasst von Anne Sofie Frølunde und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease. The condition is prevalent worldwide affecting children more than the adult population. AD is associated with a significant adverse impact on a patient’s physical, psychological, and social life. Control of symptoms and disease activity and minimizing the number of flares are the goal of AD treatment. Available treatment options for AD include topical and/or systemic therapy. Despite significant advancements in the systemic treatment landscape including biologics and tyrosine kinase inhibitors, topical therapy remains valuable in the treatment of AD. In this article, we cover the pathophysiology of AD in brief along with the definitions of reactive and proactive approach of treatment. The concept of proactive treatment with topical therapy to control the disease and prevent flares is discussed along with the supporting published evidence.
Zitieren
APA
Frølunde, A. S., & Vestergaard, C. (2023). Reactive and proactive treatment in atopic dermatitis: Long-term disease control. Indian Journal of Skin Allergy, 2, 45-50. https://doi.org/10.25259/ijsa_31_2023
Vancouver
Frølunde AS, Vestergaard C. Reactive and proactive treatment in atopic dermatitis: Long-term disease control. Indian Journal of Skin Allergy. 2023;2:45-50. doi:10.25259/ijsa_31_2023
BibTeX
@article{Frlunde2023,
author = {Frølunde, Anne Sofie and Vestergaard, Christian},
title = {Reactive and proactive treatment in atopic dermatitis: Long-term disease control},
journal = {Indian Journal of Skin Allergy},
year = {2023},
volume = {2},
pages = {45--50},
doi = {10.25259/ijsa_31_2023}
}
EUVIMED